CRISPR – Ayurved Healing

CRISPR, Genomics, and Ayurvedic Rasayana: Convergence in Longevity Science

Dr. Meera Iyer — Fri, 19 Jun 2026 10:30:00 +0000

In June 2026, the first participant was dosed in a Phase 1 trial of ER-100 for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. ER-100 uses controlled expression of the transcription factors OCT4, SOX2 and KLF4 to influence epigenetic gene-expression patterns in retinal ganglion cells. It is not a CRISPR telomere-editing treatment, and the trial is designed primarily to evaluate safety and tolerability, with visual-function measures as additional endpoints.

Ayurvedic Rasayana belongs to a different medical framework. The first chapter of the Charaka Samhita, Chikitsa Sthana, presents Rasayana as a promotive discipline concerned with longevity, health, memory, strength, sensory capacity and the excellence of bodily tissues. Modern geroscience and Rasayana can therefore be compared as two approaches to healthy aging, but they should not be described as molecularly equivalent or as demonstrations of the same mechanism.

What Rasayana Actually Claims

Charaka Samhita, Chikitsa Sthana 1, is arranged in four Rasayana sections: Abhayamalakiya, Pranakamiyam, Karaprachitiyam and Ayurvedasamutthaniyam. Verses 7–8 describe the intended fruits of properly administered Rasayana in classical Ayurvedic terms:

Dirgham ayuh: longevity or a long span of life
Smriti and medha: memory, understanding and intellectual capacity
Arogya: freedom from illness
Tarunam vayah: youthfulness
Prabha, varna and svara: lustre, complexion and excellence of voice
Deha-indriya-bala: strength of the body and sense faculties
Vak-siddhi, pranati and kanti: effective speech, esteem and radiance

The text presents two modes of administration. Kutipraveshika is an indoor regimen carried out in a specially prepared, controlled residence under supervision. Vatatapika is the outdoor method used while the person continues ordinary activities. Charaka describes the indoor method as demanding and suitable only for an appropriately selected person; it is not simply a modern wellness retreat.

dīrghamāyuḥ smṛtiṁ medhāmārogyaṁ taruṇaṁ vayaḥ | prabhāvarṇasvaraudāryaṁ dehendriyabalaṁ param ||

Rasayana is described as promoting longevity, memory, intelligence, health, youthfulness, lustre, complexion, voice, and excellent strength of body and senses.

Rasayana is also broader than a list of supplements. In the fourth section, Achara Rasayana treats truthful speech, freedom from anger, nonviolence, calm conduct, cleanliness, compassion, disciplined senses and balanced sleep as part of a continuously rejuvenative way of living. This ethical and behavioral dimension is integral to the classical account.

Charaka’s Chyavanaprasha passage describes a compound preparation made with 500 Amalaki fruits, a multi-herb decoction, ghee, oil, sugar, honey and aromatic finishing ingredients. The text also directs that its quantity should be compatible with subsequent food intake and digestion. Classical Chyavanaprasha is therefore a specific formulated avaleha, not powdered Amalaki, isolated vitamin C or an arbitrary mixture of extracts.

What Modern Longevity Research Is Actually Testing

Modern aging biology describes interconnected processes rather than one universal “aging gene.” A 2023 Cell review lists twelve hallmarks, including genomic instability, telomere attrition, epigenetic alterations, mitochondrial dysfunction, cellular senescence, chronic inflammation and altered intercellular communication. Telomere therapy, senolytics and partial epigenetic reprogramming are distinct experimental strategies within that larger landscape.

Telomeres and Telomerase

Telomeres are repeated DNA-protein structures that protect chromosome ends. They often shorten with cell division and age, but leukocyte telomere length provides only a rough estimate of biological aging and is not a complete predictor of health or lifespan by itself. In a 2012 mouse study, an adeno-associated viral vector expressing mouse TERT increased median lifespan by 24 percent in mice treated at one year of age and by 13 percent in mice treated at two years. The result applies to AAV-mediated telomerase gene delivery in mice, not to CRISPR treatment or human lifespan extension.

Cellular Senescence and Senolytics

Senescent cells have entered a durable growth-arrested state and can release inflammatory and tissue-remodeling factors collectively called the senescence-associated secretory phenotype. Senolytic drugs are designed to eliminate selected senescent cells, whereas senomorphic approaches seek to modify their harmful secretions. The first published human senolytic pilot involved 14 people with idiopathic pulmonary fibrosis who received dasatinib plus quercetin in an open-label study. A later small randomized pilot examined the same drug combination. These were pharmacological trials in a specific lung disease, not CRISPR procedures or demonstrations of human lifespan extension.

Partial Epigenetic Reprogramming

A 2020 Nature paper used adeno-associated viral delivery of OCT4, SOX2 and KLF4 in mouse retinal ganglion cells. In mouse models, controlled expression of these factors promoted axon regeneration and improved visual function while shifting DNA-methylation patterns toward a younger state. ER-100 carries this line of work into a first-in-human Phase 1 eye-disease trial in 2026. Its present clinical question is whether the intervention can be administered safely to people with optic neuropathies, not whether it reverses whole-body aging or extends human life.

Reading Rasayana Herbs Without Forcing Molecular Equivalence

The Ayurvedic Pharmacopoeia of India provides official standards for the identity, purity and strength of listed single drugs and records their classical properties and actions. Those monographs can establish what drug and plant part are meant in Ayurvedic pharmacy. They do not convert a classical Rasayana designation into proof of telomere extension, senolysis or epigenetic reprogramming.

Amalaki

The pharmacopoeial fresh-fruit drug Amalaki is the pulp of Emblica officinalis Gaertn. Its rasa are madhura, amla, katu, tikta and kashaya; its guna are laghu and ruksha; its virya is shita; and its vipaka is madhura. The monograph lists its karma as tridoshajit, vrishya, Rasayana and chakshushya, and names Chyavanaprasha as an important formulation. Charaka’s Rasayana chapter contains multiple Amalaki preparations and the classical Chyavanaprasha recipe. Amalaki therefore has a secure classical and pharmacopoeial place in Rasayana without being classified as a clinically established telomere therapy.

Ashwagandha

The pharmacopoeial Ashwagandha drug is the dried mature root of Withania somnifera Dunal. Its rasa are tikta and kashaya, its guna is laghu, its virya is ushna and its vipaka is madhura; its listed actions include Rasayana, vatakaphapaha, balya and vajikarana. Contemporary human trials of Ashwagandha preparations have mainly examined stress and sleep, using products that differ in plant part, extraction method and standardization. A branded concentrated extract is not automatically interchangeable with every classical root preparation, and Ashwagandha is not classified as a CRISPR-like senolytic.

Brahmi and Medhya Rasayana

The Ayurvedic Pharmacopoeia identifies Brahmi as the dried whole plant of Bacopa monnieri. It records madhura, tikta and kashaya rasa; laghu and sara guna; shita virya; madhura vipaka; and actions that include medhya and Rasayana. Textual precision is still necessary: Charaka Samhita Chikitsa 1.3.30–31 specifically names Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice and Shankhapushpi paste as Medhya Rasayanas, with Shankhapushpi described as especially medhya. Modern randomized trials of standardized Bacopa products have chiefly assessed attention and memory outcomes rather than Yamanaka-factor reprogramming or reversal of epigenetic age.

Methodological Comparison

A responsible comparison keeps the categories separate while allowing each to be examined rigorously. The table below contrasts experimental geroscience interventions with classical Rasayana without assigning unmeasured percentages of “age reversal” to either side.

Parameter	Experimental geroscience intervention	Classical Ayurvedic Rasayana
Primary framework	Molecular or cellular intervention directed at a defined biological process	Promotive Ayurvedic care directed toward longevity, tissue quality, strength, cognition and health
Examples	Telomerase gene delivery, senolytic drugs and controlled partial reprogramming	Classical formulations, single-drug Rasayanas, diet, conduct and supervised regimens
Specificity	Varies by platform; may target one enzyme, cell population or transcriptional program	Selected according to the person, digestive capacity, strength, season, condition and classical indication
Evidence stage	Ranges from animal experiments to small early-phase human trials	Classical textual use with modern clinical support differing by herb, formulation and measured outcome
Reversibility	Depends on the technology; genome editing, viral gene delivery and intermittent medicines are not equivalent	Dosing can be stopped, but adverse effects and herb-drug interactions may still require medical care
Quality control	Manufacturing, vector characterization, dosing and clinical-trial oversight	Correct botanical identity, plant part, pharmacopoeial purity and formulation standards
Valid outcomes	Safety, disease-specific function, biomarkers and eventually clinical benefit	Safety, classical indications, patient-centered function and prespecified modern clinical outcomes

The Biological-Age Measurement Problem

DNA-methylation clocks provide useful research biomarkers, but they are not interchangeable. Horvath’s clock estimates age from methylation at selected CpG sites across tissues. PhenoAge and GrimAge were developed to improve associations with phenotypic risk and mortality-related outcomes. Telomere length supplies different information and is best interpreted alongside other markers. A lower clock estimate after an intervention does not by itself demonstrate restored organ function, reduced disease, longer survival or comprehensive rejuvenation.

Clock results can also vary with the sampled tissue, cellular composition, laboratory method and algorithm selected. A meaningful intervention study should specify the clock in advance, preserve consistent sample handling and distinguish a statistically detectable biomarker change from a clinically important benefit.

A rigorous Rasayana trial should therefore preregister its protocol, authenticate every product, include an appropriate comparison group, report adverse events, and measure outcomes that matter clinically. Functional capacity, cognition, sleep, quality of life, disease-specific measures and laboratory safety can be assessed together with exploratory biomarkers. Numerical claims about years of age reversal require a traceable publication, a clearly named clock, transparent statistical methods and independent replication.

A Responsible Contemporary Rasayana Framework

Classical Rasayana is individualized rather than a universal stack of Chyavanaprasha, Ashwagandha, Brahmi, Amalaki and Shilajit at fixed commercial-extract doses. Even the dose ranges printed in pharmacopoeial monographs are general adult oral guidance rather than substitutes for an individualized prescription. A safer contemporary framework preserves clinical judgment:

Begin with assessment: a qualified Ayurvedic physician should consider age, agni, bala, prakriti, vikriti, current disease, medicines, diet, season and suitability before selecting a Rasayana.
Use the correct drug: botanical identity, plant part, preparation and anupana matter. Root, leaf, whole-plant powder and concentrated extract are not automatically equivalent.
Include conduct and routine: Achara Rasayana, adequate sleep, suitable food, physical activity and mental discipline belong to the classical framework rather than serving merely as optional additions to pills.
Choose pharmacopoeial quality: products should meet identity, purity and strength standards and comply with applicable limits for lead, arsenic and other heavy metals.
Avoid indiscriminate combinations: more Rasayana ingredients do not necessarily produce a stronger or safer treatment. Formulations containing metals or minerals require especially careful professional selection and quality assurance.
Monitor safety: new gastrointestinal, allergic, neurological, hepatic or other symptoms require reassessment. Ashwagandha needs particular caution in pregnancy and breastfeeding, before surgery, with thyroid or autoimmune disorders, and with medicines that may interact.

The Right Conclusion

Rasayana and modern geroscience share a broad interest in maintaining function during aging, but their concepts, interventions and standards of proof are different. Telomerase gene delivery in mice does not validate an herbal longevity claim; a classical Rasayana designation does not establish activity against a modern molecular hallmark; and partial epigenetic reprogramming in an eye-disease trial is not CRISPR-based whole-body age reversal.

The productive meeting point is research design. Classical formulations can be authenticated and administered according to coherent Ayurvedic protocols, while modern trials can measure safety, function, disease outcomes and carefully chosen biomarkers. This approach respects the source tradition without borrowing the authority of gene editing, and it allows promising Rasayana practices to be evaluated without turning analogy into proof.

This article is educational and does not constitute medical advice. Rasayana treatment should be individualized by a qualified Ayurvedic physician and coordinated with a healthcare provider, especially during pregnancy, breastfeeding, chronic illness or prescription-drug use. Herbal or mineral products should not replace established medical care. ER-100 and other cellular-reprogramming or gene-therapy interventions are experimental and should be used only within authorized clinical trials.

References

Placebo-Controlled Ashwagandha Trials 2020-2025: A Quantitative Review

Dr. Meera Iyer — Thu, 09 Apr 2026 09:00:00 +0000

Placebo-Controlled Ashwagandha Trials 2020–2025: A Quantitative Review

Placebo-controlled studies published between 2020 and 2025 examined ashwagandha for stress, anxiety, sleep, cognition, fatigue and physical performance. Stress and sleep have the largest bodies of human trial data, but the studies remain heterogeneous: they use different plant parts, extraction methods, standardization markers, doses, durations and outcome scales. This review summarizes the regimens and numerical results actually reported while distinguishing modern standardized extracts from the traditional Ayurvedic root drug.

Background: What Is Ashwagandha?

Aśvagandhā (अश्वगंधा; Withania somnifera Dunal) is represented in the Ayurvedic Pharmacopoeia of India by the dried mature root. Its name is commonly associated with the root’s characteristic horse-like smell: aśva means horse and gandha means smell. The pharmacopoeial monograph records its rasa as tikta and kaṣāya, guṇa as laghu, vīrya as uṣṇa and vipāka as madhura. Its stated actions are rasāyana, balya, vājīkaraṇa and vātakaphāpaha, indicating traditional use as a rejuvenative, strength-promoting and Vāta-Kapha-alleviating drug.

The pharmacopoeial root contains alkaloids and withanolides and has a traditional powdered-root dose of 3–6 g. This dose cannot be directly converted into milligrams of a concentrated extract. Modern trials have used root extracts, combined root-and-leaf extracts and proprietary preparations with widely differing withanolide specifications. Root and leaf have different chemical profiles, so products using these plant parts should not be treated as interchangeable. “Adaptogen” is a modern pharmacological category rather than a synonym for the classical Ayurvedic term rasāyana.

Stress and Anxiety Trials

A 2014 systematic review by Pratte and colleagues located five randomized human trials of ashwagandha for anxiety or stress-related outcomes. The studies generally favored ashwagandha, but variations in populations, products, measures and reporting prevented a formal meta-analysis, and every included trial was judged to have an unclear or high risk of bias. The review therefore did not produce the standardized mean differences sometimes attributed to it.

The frequently cited 2012 Chandrasekhar trial randomized 64 adults with chronic stress to a concentrated root extract or placebo. Participants received 300 mg twice daily for 60 days. Perceived Stress Scale scores declined by 44.0% in the extract group and 5.5% in the placebo group. Mean serum cortisol declined by 27.9% and 7.9%, respectively. This was a small, single-centre trial conducted before the 2020–2025 review period, but it remains important background for later stress studies.

A 2022 systematic review and dose-response meta-analysis included 12 randomized trials with 1,002 participants. The pooled standardized mean difference was −1.55 for anxiety and −1.75 for stress in comparisons with placebo. These apparently large estimates were accompanied by very high statistical heterogeneity—approximately 94% for anxiety and 83% for stress—and the certainty of the evidence was rated low. The pooled numbers therefore do not establish that every formulation will produce an effect of the same magnitude.

One placebo-controlled study published in 2023 randomized 54 adults with mild-to-moderate stress and anxiety; 50 completed the trial. The intervention supplied 500 mg of root extract standardized to 2.5% withanolides plus 5 mg of piperine once daily for 60 days. Scores on the Perceived Stress Scale and Generalized Anxiety Disorder-7 scale were lower than with placebo at day 60, and quality-of-life scores improved. Because this was a proprietary combination containing piperine, its findings do not automatically apply to other ashwagandha extracts.

Cortisol as a Secondary Outcome

Cortisol has been measured as a secondary biomarker in several stress trials. Reductions were reported in the 2012 trial, the 2021 sustained-release root-extract trial and the 2023 root-extract-plus-piperine trial. Cortisol results should be interpreted alongside symptoms and validated clinical scales because sampling time, biological variation and the type of cortisol specimen can influence the measurement. Human trials have not established that direct binding of withanolides to glucocorticoid receptors is the clinical mechanism of action.

Sleep Quality Trials, 2020–2025

Placebo-controlled sleep studies include both people with insomnia and participants reporting non-restorative sleep. Some trials combined questionnaire scores with actigraphy, which estimates sleep and wake periods from movement. The studies used distinct preparations and should be compared by plant part and extract specification as well as by milligram dose.

Publication	Participants	Preparation and Dose	Duration	Verified Result
Deshpande et al., 2020	150 adults with non-restorative sleep	Root-and-leaf extract, 120 mg/day	6 weeks	Subjective sleep-quality improvement was 72% with ashwagandha and 29% with placebo; actigraphy also favored the extract for several sleep measures.
Langade et al., 2021	80 adults; 40 had insomnia	Root extract, 300 mg twice daily	8 weeks	The insomnia subgroup improved in sleep quality, sleep-onset latency, morning alertness and anxiety measures compared with placebo.
Cheah et al., 2021 meta-analysis	5 trials; pooled n=372	Root extracts at 250–600 mg/day or a root-and-leaf extract at 120 mg/day	6–12 weeks	The pooled effect on overall sleep was small but statistically significant; the reported standardized mean difference was −0.59, with I²=62%.

The sleep meta-analysis found larger effects in participants with insomnia, in trials lasting at least eight weeks and in studies using 600 mg/day. These subgroup observations were based on a small collection of trials and should not be interpreted as a universal minimum dose. The 120 mg root-and-leaf extract was substantially more concentrated than ordinary root powder and cannot be compared milligram for milligram with the root extracts.

Cognitive Function, Energy and Mood

A 2021 randomized, double-blind trial enrolled 130 healthy adults with self-reported stress; 125 completed the study. Participants received one 300 mg sustained-release root-extract capsule or placebo daily for 90 days. The ashwagandha group performed better on selected Cambridge Neuropsychological Test Automated Battery measures, including paired-associate recall and total errors. It also had lower perceived-stress and sleep-quality scores, lower serum cortisol and higher psychological well-being scores. The study did not use KSM-66 or a dose of 300 mg twice daily.

A 2024 randomized trial in healthy young adults evaluated a liposomal root-and-leaf extract at 225 mg/day for 30 days, including an assessment after the initial dose. Some measures of memory, attention, vigilance and executive function favored ashwagandha, and participants reported less tension and fatigue. The improvements were not uniform across every cognitive test, and the extract differed substantially from the root-only preparations used in other trials.

Another 2024 prospective placebo-controlled study enrolled 120 adults with self-reported cognitive or energy concerns and administered 600 mg/day of root extract for eight weeks. Improvements were reported in selected measures of episodic memory, working memory, attention, energy and mood. These cognition studies involved different populations, instruments and preparations, so their results do not yet define a standard cognitive-enhancement protocol.

Physical Performance and Strength Outcomes

A 2021 systematic review and Bayesian meta-analysis concluded that ashwagandha groups generally performed better than placebo groups on measures related to strength and power, cardiorespiratory fitness, fatigue and recovery. The underlying trials were small and varied in training status, extract type, dose and outcome selection. Several of the strength studies included in that synthesis were published before 2020.

The often-cited resistance-training trial involving bench-press and leg-extension strength was published in 2015 rather than 2021. A separate 2021 randomized study evaluated cardiorespiratory endurance in healthy athletic adults. A 2024 eight-week placebo-controlled study used 600 mg/day of a standardized root extract in adults performing resistance training and assessed physical endurance and maximal oxygen uptake. Collectively, these studies support continued investigation of exercise outcomes but do not establish equivalence among all ashwagandha products.

Thyroid Outcomes

The randomized trial in 50 participants with subclinical hypothyroidism was published in 2018, not 2020. Participants received 300 mg of root extract twice daily or placebo for eight weeks. The intervention lowered thyroid-stimulating hormone and increased T3 and T4 relative to placebo. These hormonal changes are a reason for clinical caution rather than a general recommendation to treat hypothyroidism with ashwagandha. Case reports of thyrotoxicosis and the possibility of interactions with thyroid-hormone medicines make professional monitoring important.

Regimens Studied Across Clinical Domains

No single “effective ashwagandha dose” can be derived from the trials because extract concentration, plant part and standardization differ. The following table records representative regimens rather than prescribing them. The Ayurvedic Pharmacopoeia’s 3–6 g dose applies to powdered root drug and should remain separate from concentrated-extract dosing.

Clinical Domain	Representative Placebo-Controlled Regimens	Typical Study Period	Interpretive Note
Stress and anxiety	300 mg root extract twice daily; 500 mg root extract with 5 mg piperine once daily; other trials used 240–1,250 mg/day of extract	6–12 weeks	Pooled benefits were reported, but product heterogeneity and low-certainty meta-analytic estimates limit dose comparisons.
Sleep	120 mg/day concentrated root-and-leaf extract or 300 mg root extract twice daily	6–8 weeks	The pooled sleep effect was small, with larger subgroup effects among participants with insomnia.
Cognition and mood	300 mg/day sustained-release root extract; 225 mg/day liposomal root-and-leaf extract; 600 mg/day root extract	30–90 days	Selected outcomes improved, but the trials used different cognitive batteries and populations.
Physical performance	Various standardized root extracts, commonly studied alongside structured exercise	8–12 weeks	The evidence base combines endurance, strength, recovery and oxygen-uptake outcomes rather than one uniform endpoint.

Trial Quality and Limitations

Most placebo-controlled ashwagandha studies have been small and short, commonly lasting four to twelve weeks. Stress, anxiety and sleep trials frequently rely on participant-reported scales, although some also include cortisol testing, actigraphy or computerized cognitive assessments. Different eligibility criteria and outcome instruments complicate comparisons, while substantial heterogeneity in the stress and sleep meta-analyses reduces confidence in a single pooled effect size.

Several influential trials evaluated named proprietary extracts and disclosed manufacturer employment, commercial sponsorship or fee-for-service funding. Such disclosure does not invalidate a result, but independent replication using clearly characterized products is important. Reporting the botanical name alone is insufficient: a clinically interpretable product description should identify the plant part, extraction method, daily quantity, standardization marker and amount of the standardized constituents.

Ayurvedic Interpretation and Modern Extracts

The official Ayurvedic monograph describes the mature root and records rasāyana, balya, vājīkaraṇa and Vāta-Kapha-alleviating actions. It also lists traditional therapeutic uses including daurbalya, kṣaya, vātaroga, śotha and klaibya. These Ayurvedic categories should be presented in their own clinical framework rather than translated directly into claims about cortisol, generalized anxiety disorder, athletic performance or specific neurotransmitters.

Likewise, a concentrated root-and-leaf capsule standardized to withanolide glycosides is not the same intervention as pharmacopoeial root powder. Modern trial results apply most directly to the extract and population actually tested. Traditional use, pharmacopoeial quality standards and contemporary randomized trials can inform one another, but they do not make all preparations or doses equivalent.

Safety Profile

Ashwagandha was generally well tolerated during trials lasting up to approximately three months. Common reported effects include stomach upset, nausea, loose stools and drowsiness. Long-term safety over many months or years has not been established. Rare cases of acute liver injury have been associated with products containing ashwagandha, although the contents of every implicated product were not independently verified and some contained additional ingredients.

Ashwagandha may alter thyroid function and may interact with thyroid medicines, sedatives, immunosuppressants, antihypertensive drugs and antidiabetes medicines. Specialist advice is appropriate for people with liver disease, thyroid or other endocrine disorders, autoimmune disease, hormone-sensitive prostate cancer or complex medication regimens. Pregnant and breastfeeding individuals should avoid self-prescribing ashwagandha and seek individual guidance from a qualified healthcare professional.

Disclaimer

This article is for educational purposes and is not a diagnosis, prescription or substitute for medical care. Extract specifications and doses used in trials should not be copied without considering medical history, medicines, pregnancy status and product quality. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before beginning ashwagandha, particularly when treating persistent anxiety, insomnia, thyroid disease or another diagnosed condition.

Practical monitoring note: When a clinician recommends a supervised trial, record the product name, plant part, extract ratio or standardization, daily dose, timing, baseline symptoms and adverse effects. Stop the product and obtain medical assessment for jaundice, dark urine, marked itching, persistent abdominal symptoms, palpitations, tremor or other significant new symptoms.